Navidea Biopharmaceuticals Performance
| NAVBDelisted Stock | USD 0.0001 0.00 0.00% |
Navidea Biopharmaceutica holds a performance score of 11 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 13.72, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Navidea Biopharmaceutica will likely underperform. Use Navidea Biopharmaceutica variance, as well as the relationship between the skewness and day typical price , to analyze future returns on Navidea Biopharmaceutica.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Navidea Biopharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Navidea Biopharmaceutica sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Navidea |
Navidea Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 0.01 in Navidea Biopharmaceuticals on November 10, 2025 and sell it today you would earn a total of 0.00 from holding Navidea Biopharmaceuticals or generate 0.0% return on investment over 90 days. Navidea Biopharmaceuticals is currently generating 10.6667% in daily expected returns and assumes 74.9682% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Navidea, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Navidea Biopharmaceutica Target Price Odds to finish over Current Price
The tendency of Navidea Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 58.22 |
Based on a normal probability distribution, the odds of Navidea Biopharmaceutica to move above the current price in 90 days from now is about 58.22 (This Navidea Biopharmaceuticals probability density function shows the probability of Navidea Pink Sheet to fall within a particular range of prices over 90 days) .
Navidea Biopharmaceutica Price Density |
| Price |
Predictive Modules for Navidea Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Navidea Biopharmaceutica. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Navidea Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Navidea Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Navidea Biopharmaceutica is not an exception. The market had few large corrections towards the Navidea Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Navidea Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Navidea Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 4.50 | |
β | Beta against Dow Jones | 13.72 | |
σ | Overall volatility | 0.000053 | |
Ir | Information ratio | 0.11 |
Navidea Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Navidea Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Navidea Biopharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Navidea Biopharmaceutica is not yet fully synchronised with the market data | |
| Navidea Biopharmaceutica is way too risky over 90 days horizon | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica appears to be risky and price may revert if volatility continues | |
| Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
Navidea Biopharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Navidea Pink Sheet often depends not only on the future outlook of the current and potential Navidea Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Navidea Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.3 M | |
| Cash And Short Term Investments | 2 M |
Navidea Biopharmaceutica Fundamentals Growth
Navidea Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Navidea Biopharmaceutica, and Navidea Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Navidea Pink Sheet performance.
| Return On Equity | -11.0 | |||
| Return On Asset | -1.22 | |||
| Current Valuation | 3.5 M | |||
| Shares Outstanding | 100.08 M | |||
| Price To Earning | 0.53 X | |||
| Price To Book | 8.16 X | |||
| Price To Sales | 84.14 X | |||
| Revenue | 65.65 K | |||
| EBITDA | (14.05 M) | |||
| Cash And Equivalents | 328.01 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.43 M | |||
| Debt To Equity | 1.20 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (8.99 M) | |||
| Earnings Per Share | (0.39) X | |||
| Total Asset | 4.37 M | |||
| Retained Earnings | (388 M) | |||
| Current Asset | 12.58 M | |||
| Current Liabilities | 6.18 M | |||
About Navidea Biopharmaceutica Performance
By analyzing Navidea Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Navidea Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Navidea Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Navidea Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 11 people.Things to note about Navidea Biopharmaceutica performance evaluation
Checking the ongoing alerts about Navidea Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Navidea Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Navidea Biopharmaceutica is not yet fully synchronised with the market data | |
| Navidea Biopharmaceutica is way too risky over 90 days horizon | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica appears to be risky and price may revert if volatility continues | |
| Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
- Analyzing Navidea Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Navidea Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Navidea Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Navidea Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Navidea Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Navidea Biopharmaceutica's pink sheet. These opinions can provide insight into Navidea Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |